About the Authors
- Zongchao Han
-
Affiliation Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
- Shannon M. Conley
-
Affiliation Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
- Rasha Makkia
-
Affiliation Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
- Junjing Guo
-
Affiliation Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
- Mark J. Cooper
-
Affiliation Copernicus Therapeutics, Inc., Cleveland, Ohio, United States of America
- Muna I. Naash
-
* E-mail: Muna-Naash@ouhsc.edu
Affiliation Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
Competing Interests
MJC is an employee of Copernicus Therapeutics and owns stock and stock options in the company. There are issued and pending patents covering DNA nanoparticle compositions and their use as therapy for ocular disease. Nanoparticles are in development at Copernicus Therapeutics and there are no current marketed products. This information does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: ZH MIN. Performed the experiments: ZH SMC RM JG MIN. Analyzed the data: ZH SMC MIN. Contributed reagents/materials/analysis tools: MJC MIN. Wrote the paper: ZH SMC MJC MIN.